Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option

Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment 
Option 
SAN DIEGO, CA -- (Marketwired) -- 01/13/14 --  Adamis Pharmaceuticals
Corporation (NASDAQ: ADMP) today announced the full exercise of the
over-allotment option granted to the underwriters to purchase an
additional 558,000 shares of common stock at a public offering price
of $5.95 per share in connection with its previously announced
underwritten public offering of 3,720,000 shares of common stock,
bringing the expected total gross proceeds from the offering to
approximately $25,454,100, before underwriting discounts and
commissions and other offering expenses and before any use of the
proceeds by the company. The sale of the additional shares is
expected to close on January 16, 2014, subject to customary closing
conditions.  
CRT Capital Group, LLC acted as sole book-running manager for the
offering, and Newport Coast Securities, Inc. acted as co-manager of
the offering. 
A registration statement on Form S-1 relating to the shares of common
stock offered by the company was filed with the Securities and
Exchange Commission and is effective. The final prospectus relating
to the offering, and any supplements thereto, have been filed with
the SEC and are available on the SEC's web site at
http://www.sec.gov. Copies of the final prospectus may be obtained
from the SEC's web site or from CRT Capital Group LLC, 262 Harbor
Drive, Stamford, CT 06902. 
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale is not permitted. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. The company's
current specialty pharmaceutical product candidates include the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The company's vaccine product candidates and cancer drug
product candidates under research and development include TeloB-VAX,
a cell-based therapeutic cancer vaccine and three drugs, APC-100,
APC-200, and APC-300, for the treatment of prostate cancer. 
Adamis Contacts 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.